chronic plaque psoriasis. Almost 50% of patients treated with adalimumab achieved an assessment of clear or minimal with at least a two-grade improvement from baseline in signs and symptoms of ngernail psoriasis compared to 7% percent of placebo patients.21
The treatment plan for every patient must be individualized taking into account nail psoriasis severity, involvement of the nail matrix, nail bed or both, ngernails vs. toenails, number of nails affected, concomitant skin and joint involvement, patient lifestyle, and adherence to a treatment regimen, comorbidities medications, and impact on quality of life. The recent FDA approval of adalimumab ngernail psoriasis data in the package insert for this drug is a major win for the treatment of nail psoriasis. It is hoped that this approval will improve access to biologics for our nail psoriasis patients, thus improving their functionality and quality of life.
Dr. Lipner has no con icts of interest relevant to the content of the submission. Dr. Lebwohl is an employee of the Mount Sinai Medical Center, which receives research funds from AbbVie, Amgen, Anacor, Aqua, Celgene, Lilly, Janssen Biotech, LEO Pharma, Merz, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Valeant.
Shari R. Lipner MD PhD
Weill Cornell Medicine, Department of Dermatology, New York, NY
Mark G. Lebwohl MD
Mount Sinai Medical Center, Department of Dermatology, New York, NY
- Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Amer Acad Dermatol 2007;57(1):1-27.
- Samman PD, Fenton DA. The Nails in Disease. 5th edition ed. London, England: Butterworth-Heinemann Ltd, 1994.
- Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003;7(4):317-21.
- Armesto S, Esteve A, Coto-Segura P, et al. [Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients]. Actas Dermosi liogr 2011;102(5):365-72.
- Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Derma- tol 1997;136(5):786-9.
- Rigopoulos D, Papanagiotou V, Daniel R, 3rd, et al. Onychomycosis in patients with nail psoriasis: a point to point discussion. Mycoses 2017;60(1):6-10.
- de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996;193(4):300-3.
- van der Velden HM, Klaassen KM, van de Kerkhof PC, et al. The impact of ngernail psoriasis on patients’ health-related and disease-specific quality of life. Dermatology 2014;229(2):76-82.
- Klaassen KM, van de Kerkhof PC, Pasch MC. Nail Psoriasis, the unknown burden of disease. JEADV 2014;28(12):1690-5.
- Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire- based survey. Br J Dermatol 2013;169(2):314-9.
- Gumusel M, Ozdemir M, Mevlitoglu I, et al. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. JEADV 2011;25(9):1080-4.
- Demirsoy EO, Kiran R, Salman S, et al. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. J Drugs Dermatol 2013;12(9):1039-43.
- Sanchez-Regana M, Sola-Ortigosa J, Alsina-Gibert M, et al. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). JEADV 2011;25(5):579-86.
- Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009;145(3):269-71.
- Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Amer Acad Dermatol 2015;73(1):37-49.
- Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ES- TEEM 2). Br J Dermatol 2015;173(6):1387-99.
- Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Amer Acad Dermatol 2016;74(1):134-42.
- Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs 2016;76(6):675-705.
- Crowley JJ, Weinberg JM, Wu JJ, et al. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 2015;151(1):87-94.
- Abbvie. News release. 2017. https://news.abbvie.com/news/us-fda-ap- proves-addition-moderate-to-severe- ngernail-psoriasis-data-to-abbvies-hu- mira-adalimumab-prescribing-information.htm. Last accessed 4/11/17
- Abbvie. News release. 2016. https://news.abbvie.com/news/abbvie-pres- ents-initial-data-from-pivotal-phase-3-trial-evaluating-efficacy-and-safety- humira-adalimumab-for-moderate-to-severe- ngernail-psoriasis-in-adult-pa- tients-at-psoriasis-2016-congress.htm. Last accessed 4/11/17